title: Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.
abstract: Ipilimumab, an anticancer drug, is an anti-CTLA4 monoclonal antibody. It is used in treatment of disseminated melanoma. Therapy is associated with high risk of complications. One of the most serious, although one of the rarest is perforation of gastrointestinal tract. In this case report we describe a 52-year old male, with disseminated melanoma with unknown starting point, treated with anti- CTLA4 monoclonal antibody. After 3rd dose of drug administration, bloody diarrhea and acute abdominal pain occurred as a symptom of gastrointestinal perforation. A single perforation was sutured during laparotomy. Symptoms of acute abdomen returned after 10 days. Pus-faecalperitonitis, symptoms of necro-hemorrhagic colitis and multilocal perforation of the colon were found during relaparotomy. Pancolectomy with end ileostomy was performed. Few hours since relaparotomy pacient died due to multiple organ failure. The purpose of this case report is to draw attention to a risk of multilocal colon perforation in patient treated with ipilumumab.
authors.forename: Paweł
authors.initials: P
authors.lastname: Dilling
authors.forename: Jakub
authors.initials: J
authors.lastname: Walczak
authors.forename: Paweł
authors.initials: P
authors.lastname: Pikiel
authors.forename: Wiesław J
authors.initials: WJ
authors.lastname: Kruszewski
mesh_terms: D000006:Abdomen, Acute / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D010538:Peritonitis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab